Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections
Nisreen M.A. Okba, V. Stalin Raj, Ivy Widjaja, Corine H. GeurtsvanKessel, Erwin de Bruin, Felicity D. Chandler, Wan Beom Park, Nam-Joong Kim, Elmoubasher A.B.A. Farag, Mohammed Al-Hajri, Berend-Jan Bosch, Myoung-don Oh, Marion P.G. Koopmans, Chantal B.E.M. Reusken, and Bart L. Haagmans
Author affiliations: Erasmus Medical Center, Rotterdam, the Netherlands (N.M.A. Okba, V.S. Raj, C.H. GeurtsvanKessel, E. de Bruin, F.D. Chandler, M.P.G. Koopmans, C.B.E.M. Reusken, B.L. Haagmans); Utrecht University, Utrecht, the Netherlands (I. Widjaja, B.-J. Bosch); Seoul National University College of Medicine, Seoul, South Korea (W.B. Park, N.-J. Kim, M.-D. Oh); Ministry of Public Health, Doha, Qatar (E.A.B.A. Farag, M. Al-Hajri)
Main Article
Table 2
Specificity and sensitivity of assay platforms for the detection of MERS-CoV antibodies among PCR-confirmed cases*
Area under the ROC curve
|
|
|
|
Area
|
1
|
0.9893
|
0.7348
|
0.9481
|
SE
|
0
|
0.005409
|
0.07513
|
0.01767
|
95% CI
|
1–1
|
0.9787–0.9999
|
0.5876–0.8821
|
0.9134–0.9827
|
p value |
<0.0001 |
<0.0001 |
<0.0001 |
<0.0001 |
Main Article
Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.